Vera Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Vera Therapeutics, Inc. filed this Form 8-K regarding its 2023 Annual Meeting of Stockholders held on May 10, 2023. The filing was signed on May 16, 2023. As of the March 17, 2023 record date, 44,261,109 shares of Class A common stock were outstanding and entitled to vote. Vera’s Class A common stock trades on Nasdaq under the symbol VERA.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating performance, or other financial metrics.
Material Changes Versus the Prior Comparable Period
- Stockholders elected Maha Katabi, Ph.D., Michael M. Morrissey, Ph.D., and Patrick G. Enright as Class II directors, each to serve until the 2026 Annual Meeting or until a successor is elected and qualified.
- Stockholders ratified the Audit Committee’s selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Voting Results, Outlook, and Risks
| Proposal | Result | Voting Results |
|---|---|---|
| Election of Maha Katabi, Ph.D. | Approved | 27,427,581 for; 1,803,342 withheld; 6,360,591 broker non-votes |
| Election of Michael M. Morrissey, Ph.D. | Approved | 25,666,331 for; 3,564,592 withheld; 6,360,591 broker non-votes |
| Election of Patrick G. Enright | Approved | 29,205,775 for; 25,148 withheld; 6,360,591 broker non-votes |
| Ratification of KPMG LLP | Approved | 35,575,486 for; 3,251 against; 12,777 abstentions; no broker non-votes |
The filing contains no management guidance, business outlook, contingency disclosures, unusual items, or new risk-factor discussion. Broker non-votes were reported for the director elections but not for the auditor ratification.
Key Facts for Investors to Verify
- Confirm the continued board composition and the Class II directors’ terms through the 2026 annual meeting.
- Confirm KPMG LLP’s appointment for the fiscal year ending December 31, 2023.
- Review Vera’s periodic financial filings separately for financial results, cash runway, debt, liquidity, clinical-program developments, and risk factors, none of which are addressed in this 8-K.
- Note that the filing’s report date is May 10, 2023, while the signature date is May 16, 2023.